NCT04427475Unknown不适用
Study on the Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer by Detection of Plasma Exosomes
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- PD-L1 expression profiles of exosomes
研究概览
简要总结
To detect the difference of PD-L1 and miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy, and to explore the potential of plasma exosomes PD-L1 and miRNAs as biomarkers to predict the therapeutic effect of NSCLC on anti-PD-1 / PD-L1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign informed consent.
- •The age is greater than or equal to 18 years old.
- •There is at least one measurable focus according to the RECIST 1.1 standard
- •EGFR / ALK detection is not needed in patients with metastatic (stage IV) EGFR / ALK wild-type NSCLC confirmed by histology or cytology and in patients with squamous cell carcinoma.
- •Cohort 1: patients receiving anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment Cohort 2: patients who received the second-line treatment of anti-PD-1 single drug (nafulizumab) for the progress of disease after chemotherapy with platinum containing dual drugs
- •ECoG score is 0, 1 or
- •No serious blood system, heart, lung, liver and kidney dysfunction and immune deficiency.
- •Hemoglobin (HB) ≥ 9g / dl; leukocyte (WBC) ≥ 3 * 109 / L; neutrophil (ANC) ≥ 1.5 * 109 / L; platelet (PLT) ≥ 75 * 109 / L.
- •Men or women of childbearing age are willing to take contraceptive measures in the experiment.
- •Estimated survival time ≥ 3 months.
排除标准
- •Histologically, small cell and non-small cell mixed lung cancer.
- •Pregnant or nursing women.
- •Any unresponsive > CTCAE Level 2 toxicity caused by past anti-tumor treatment
- •Serum creatinine clearance < 30 ml / min (calculated by Cockcroft Gault formula)
- •Liver dysfunction, defined as:
- •Serum (total) bilirubin > 1.5 × upper limit of normal value (ULN)
- •Serum AST / SGOT or ALT / SGPT > 2.5 × ULN (liver metastasis > 5 × ULN)
- •Alkaline phosphatase level > 2.5 × ULN (liver metastasis > 5 × ULN, or bone) at baseline Transfer patients > 10 × ULN)
- •Have a history of uncontrollable or symptomatic angina, arrhythmia or congestive heart failure.
- •Symptomatic brain metastasis or meningeal metastasis.
- •In the past 5 years, she has had or is suffering from other histological types of malignant tumors, except for cervical carcinoma in situ and fully treated skin basal cell carcinoma or squamous cell carcinoma.
- •Have active, or have had and may recur autoimmune diseases. However, subjects with type I diabetes, hypothyroidism requiring hormone replacement therapy only, skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia), or no relapse without external triggers are expected.
- •Diagnosis of immunodeficiency or systemic hormone therapy (e.g., hormone therapy equivalent to > 10 mg prednisone per day) or any other form of immunosuppressive therapy within 7 days before the first administration.
- •Patients with known history of human immunodeficiency virus (HIV) infection and / or acquired immunodeficiency syndrome. Subjects with active hepatitis B or active hepatitis C
- •Grade 2 pneumonia caused by radiotherapy and chemotherapy (grade 2 pneumonia without systemic hormone treatment recovers to grade 1 or below within 14 days, if the researcher judges that there is no risk of recurrence, it can be included in the group for screening).
- •Have interstitial lung disease and the disease has symptoms.
- •During the study period, radiotherapy is planned for the target focus.
- •Plan to use other anti-tumor therapy during the study period.
- •Patients with serious or uncontrolled systemic diseases who are not suitable for the study or may affect the compliance of the other party's case. Subjects' complications or other conditions may affect compliance with the protocol or may not be suitable for the study.
研究组 & 干预措施
pabolizumab
Other
Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
干预措施: pabolizumab (Drug)
nafulizumab
Other
Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
干预措施: nafulizumab (Drug)
结局指标
主要结局
PD-L1 expression profiles of exosomes
时间窗: through study completion, an average of 1 year
detect the difference of PD-L1 expression profiles of exosomes in NSCLC patients before and after immunotherapy
miRNA expression profiles of exosomes
时间窗: through study completion, an average of 1 year
detect the difference of miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy
次要结局
未报告次要终点
研究者
Jialei Wang
Principal Investigator
Fudan University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 BiopsyAdvanced Gastric CarcinomaImmunotherapyNCT05334849Lin Chen80
已完成
不适用
Prognostic Immune Biomarkers in HNSCCHead and Neck CancerSquamous Cell CarcinomaNCT05941676University Hospital Ostrava55
终止
不适用
Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based ChemotherapyNSCLC Stage IVNSCLC, Stage IIICNCT04676386Addario Lung Cancer Medical Institute29
已完成
不适用
The Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.NSCLCNCT03073902Xinqiao Hospital of Chongqing80
进行中（未招募）
不适用
Analysis of Circulating Exosomes in Melanoma PatientsMelanomaNCT05744076Centre Hospitalier Universitaire de Besancon150